Mark S. Ordan - Aug 30, 2021 Form 4 Insider Report for MEDNAX, INC. (MD)

Role: Chief Executive Officer, Director
Signature: /s/ Dominic J. Andreano, as Attorney-in-Fact
Stock symbol: MD
Transactions as of: Aug 30, 2021
Transactions value $: -$3,333,550
Form type: 4
Date filed: 8/31/2021, 07:49 PM
Next filing: Jan 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MD	Common Stock	Options Exercise	$1.68M	+95K	+45.58%	$17.65	303K	Aug 30, 2021	Direct	F1
transaction	MD	Common Stock	Sale	-$3.33M	-95K	-31.31%	$35.09	208K	Aug 30, 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MD	Employee Stock Option (right to buy)	Options Exercise	-$1.68M	-95K	-17.26%	$17.65	455K	Aug 30, 2021	Common Stock	95K	$17.65	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired upon exercise of Stock Options granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan").
F2	The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date.